Calyptus Pharmaceuticals Announces Approval of Arformoterol Tartrate Inhalation Solution, EQ 0.015 mg Base/2 ml
2022-08-24
合作
PRINCETON, N.J., Aug. 24, 2022 /PRNewswire/ -- Calyptus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration ("FDA") granted approval to an Abbreviated New Drug Application (ANDA) for a generic version of Brovana
® (Arformoterol Tartrate inhalation solution,
EQ 0.015 mg Base/2 ml) to Calyptus' partner - VistaPharm, Inc., ("VistaPharm" - a Pharmaceutical Associates, Inc company). Calyptus co-developed the product in collaboration with VistaPharm. Arformoterol Tartrate inhalation solution,
EQ 0.015 mg Base/2 ml is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Arformoterol Tartrate inhalation solution is for use by nebulization only.
Calyptus Co-founders - Sujeet Singh, Dr. Puiho Yuen and Shubhayu Sinharoy said, "We are thrilled with this approval in partnership with VistaPharm. We believe that combining Calyptus' know-how and expertise with partners is key to bringing affordable medicines to patients and creating shared success. The successful development, and approval of a generic formulation of Arformoterol Tartrate inhalation solution is a testimony to these efforts".
According to IQVIA™, a leading healthcare data and analytics provider, U.S. annual sales for Arformoterol Tartrate inhalation solution,
EQ 0.015 mg Base/2 ml for the 12 months ended June 2022 were approximately $104 million.
About Calyptus
Calyptus is a pharmaceutical company based in Princeton, N.J., whose mission is to improve lives of patients by increasing access and affordability of quality medicines. Founded in 2017, Calyptus is developing a portfolio of sterile products (generic ANDAs and specialty 505(b)2s) that resolve technological complexity, create accelerated regulatory pathways, bridge unmet medical needs and overcome market access barriers. Additional information is available on Calyptus' website at www.calyptuspharma.com
CONTACT
Name: Shubhayu Sinharoy, COO Calyptus Pharmaceuticals, Inc.
Email: [email protected]
Phone: 269-873-0430
Website: www.calyptuspharma.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。